Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [815]

ASCO Direct Highlights 2022: prostate cancer highlights

Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA

ASCO Direct Highlights 2022: prostate cancer highlights ( Dr Chandler Park - Baptist Health Hardin, Elizabethtown, USA )

ASCO Direct Highlights 2022: lung cancer highlights

Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA

ASCO Direct Highlights 2022: lung cancer highlights ( Dr Tom Stinchcombe - Duke Cancer Center, Durham, USA )

War in Ukraine: Global cancer aid to support refugees

Dr Horia Vulpe , Dr Ruslan Baltaga

War in Ukraine: Global cancer aid to support refugees ( Dr Horia Vulpe , Dr Ruslan Baltaga )

War in Ukraine: The International Brain Tumour Alliance's response to aiding...

Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance

War in Ukraine: The International Brain Tumour Alliance's response to aiding refugees during the crisis ( Kathy Oliver - Chair and Co-Director, International Brain Tumour Alliance )

ASCO and WHO to collaborate on quality indicators for cancer facilities

Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland

ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

Biomarker guidance allows patients 55 or older with low-grade luminal A-type...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to avoid radiation therapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard...

Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab and nivolumab immunotherapy could become new standard of care for resectable stage III melanoma ( Dr Christian U. Blank - The Netherlands Cancer Institute, Amsterdam, Netherlands )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide...

Dr Martin McCabe- University of Manchester, Manchester, England

$Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients ( Dr Martin McCabe- University of Manchester, Manchester, England )$

More from ecancer